Stock DNA
Pharmaceuticals & Biotechnology
VND 1,835,638 Million (Small Cap)
13.00
NA
0.00%
-0.64
2.90%
0.47
Revenue and Profits:
Net Sales:
515,309 Million
(Quarterly Results - Mar 2025)
Net Profit:
37,461 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.23%
0%
5.23%
6 Months
12.78%
0%
12.78%
1 Year
19.48%
0%
19.48%
2 Years
9.11%
0%
9.11%
3 Years
20.33%
0%
20.33%
4 Years
-60.42%
0%
-60.42%
5 Years
-46.38%
0%
-46.38%
F.I.T. Investment JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.39%
EBIT Growth (5y)
48.57%
EBIT to Interest (avg)
0.50
Debt to EBITDA (avg)
0.34
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.36
Tax Ratio
30.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.04%
ROE (avg)
4.00%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
0.40
EV to EBIT
-13.01
EV to EBITDA
-3.40
EV to Capital Employed
-0.51
EV to Sales
-0.37
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
2.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
515,308.60
678,485.10
-24.05%
Operating Profit (PBDIT) excl Other Income
114,523.30
49,616.20
130.82%
Interest
18,418.90
15,218.60
21.03%
Exceptional Items
0.00
0.00
Consolidate Net Profit
37,461.50
24,144.80
55.15%
Operating Profit Margin (Excl OI)
71.00%
15.80%
5.52%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -24.05% vs 70.46% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 55.15% vs -13.83% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,953,658.10
1,745,767.60
11.91%
Operating Profit (PBDIT) excl Other Income
181,068.90
176,677.80
2.49%
Interest
53,562.00
69,858.10
-23.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
176,503.30
-77,624.50
327.38%
Operating Profit Margin (Excl OI)
20.10%
15.70%
0.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 11.91% vs -8.94% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 327.38% vs -208.41% in Dec 2023
About F.I.T. Investment JSC 
F.I.T. Investment JSC
Pharmaceuticals & Biotechnology
F.I.T Investment Joint Stock Company is a Vietnam-based company engaged in the investment industry. The Company provides consulting services, including corporate brand development consulting services, personal finance services, insurance brokerage services and real estate services. Its investment activities include financial investment activities, real estate investment activities, investments into subsidiaries and affiliates. The Company operates in five segments: listed corporation investment opportunity consulting services, service rendering, real estate trading, real estate management and leasing, and other activities. During the year ended December 31, 2012, 53% of the Company's net revenue came from the service rendering segment.
Company Coordinates 
Company Details
Level 16 - Center Bldg -Hapulco Cmplx, No 1 Ngyn Hy Tng St,Thanh Xuan Trung Wrd, Thanh Xuan District, HANOI None : None
Registrar Details






